



#5A/jw  
10.29.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: EIS-SCHWARTZ=21

In re Application of:	)	Conf. No.: 1157
EIS-SCHWARTZ et al.	)	
	)	Art Unit: 1646
	)	
Appln. No.: 09/893,344	)	Examiner: J. Andres
	)	
Filed: June 28, 2001	)	Washington, D.C.
	)	
For: USE OF POLY-GLU, TYR AND	)	October 23, 2002
T CELLS ACTIVATED...	)	
	)	

RECEIVED

OCT 28 2002

TECH CENTER 1600/2900

AMENDMENT

Honorable Commissioner of Patents  
Washington, D.C. 20231

Sir :

In response to the Office Action of September 25,  
2002, primarily in the nature of a requirement for restriction,  
please amend as follows:

IN THE CLAIMS

Please add new claims 16-31 as follows:

--16(new). A pharmaceutical composition comprising

A<sup>1</sup> a pharmaceutically acceptable carrier and an agent selected  
from the group consisting of (a) poly-Glu,Tyr and (b) T cells  
which have been activated by poly-Glu,Tyr.--

--17(new). A pharmaceutical composition according  
to claim 16 wherein the agent is poly-Glu,Tyr.--

--18(new). A pharmaceutical composition according  
to claim 17, wherein said poly-Glu,Tyr is administered in a

10/24/2002 SSESHE1 00000015 09893344 234.00 DP  
01 FC:1202